Vaccinogen
Vaccinogen develops personalized cancer immunotherapies using a patient's own tumor cells, with a stated focus on reducing recurrence after surgery for colon cancer. Its pipeline also includes antibody-based approaches and a proposed liquid biopsy assay.
Industries
N/A
Vaccinogen is currently seeking investment
Vaccinogen is seeking a late-stage investment in the range of 50m-plus
Patents
Products
A personalized treatment made from a patient's resected tumor cells and an immune-stimulating adjuvant, intended to reduce cancer recurrence after surgery. The company describes it as being studied for colon cancer.
Antibody candidates derived from B-cell responses observed during treatment research. The company describes potential applications in cancer diagnostics and therapeutics.
Investigational antibody-based candidates intended to direct T cells toward cancer cells expressing cross-reactive antigens.
A proposed cancer screening assay using human monoclonal antibodies; the source describes it as a development goal.
A personalized treatment made from a patient's resected tumor cells and an immune-stimulating adjuvant, intended to reduce cancer recurrence after surgery. The company describes it as being studied for colon cancer.
Antibody candidates derived from B-cell responses observed during treatment research. The company describes potential applications in cancer diagnostics and therapeutics.
Investigational antibody-based candidates intended to direct T cells toward cancer cells expressing cross-reactive antigens.
A proposed cancer screening assay using human monoclonal antibodies; the source describes it as a development goal.
Expertise Areas
- Cancer immunotherapy
- Personalized cell-based treatments
- Colon cancer research
- Antibody discovery and development
Key Technologies
- Autologous tumor-cell immunotherapy
- Bacillus Calmette-Guérin adjuvant
- Human monoclonal antibodies
- Bispecific T-cell engagers
Key People
Michael G. Hanna, Jr.
Founder and Chief Scientific Officer and former Director of the National Cancer Institute Frederick Cancer Research Center
Michael G. Hanna, Jr.
Founder and Chief Scientific Officer and former Director of the National Cancer Institute Frederick Cancer Research Center
News & Updates
The company states that the FDA approved its 550-patient pivotal trial protocol and granted Fast Track designation and a Special Protocol Assessment.
The company states that the FDA approved its 550-patient pivotal trial protocol and granted Fast Track designation and a Special Protocol Assessment.